CA3212816A1 - C5ar1 inhibitors for treating hypersensitivity reactions to taxanes - Google Patents

C5ar1 inhibitors for treating hypersensitivity reactions to taxanes Download PDF

Info

Publication number
CA3212816A1
CA3212816A1 CA3212816A CA3212816A CA3212816A1 CA 3212816 A1 CA3212816 A1 CA 3212816A1 CA 3212816 A CA3212816 A CA 3212816A CA 3212816 A CA3212816 A CA 3212816A CA 3212816 A1 CA3212816 A1 CA 3212816A1
Authority
CA
Canada
Prior art keywords
phenyl
c5ar1
group
alkyl
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3212816A
Other languages
English (en)
French (fr)
Inventor
Marcello Allegretti
Andrea Aramini
Piergiorgio AMENDOLA
Laura Brandolini
Maria Candida Cesta
Anna SIRICO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21163292.2A external-priority patent/EP4059497A1/en
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of CA3212816A1 publication Critical patent/CA3212816A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3212816A 2021-03-17 2022-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes Pending CA3212816A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21163292.2A EP4059497A1 (en) 2021-03-17 2021-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP21163292.2 2021-03-17
EP21217382.7 2021-12-23
EP21217382 2021-12-23
PCT/EP2022/057007 WO2022195017A1 (en) 2021-03-17 2022-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Publications (1)

Publication Number Publication Date
CA3212816A1 true CA3212816A1 (en) 2022-09-22

Family

ID=81307212

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3212816A Pending CA3212816A1 (en) 2021-03-17 2022-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Country Status (11)

Country Link
US (1) US20240180888A1 (https=)
EP (1) EP4308114B1 (https=)
JP (1) JP2024512472A (https=)
BR (1) BR112023018826A2 (https=)
CA (1) CA3212816A1 (https=)
DK (1) DK4308114T3 (https=)
FI (1) FI4308114T3 (https=)
HR (1) HRP20260351T1 (https=)
IL (1) IL305727A (https=)
LT (1) LT4308114T (https=)
WO (1) WO2022195017A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025193888A1 (en) * 2024-03-14 2025-09-18 Vanqua Bio, Inc. Pyridazinone c5ar1 antagonists and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1261275A (zh) * 1997-05-27 2000-07-26 巴克·诺顿药物有限公司 给予病人口服紫杉烷类药物的方法和组合物
CA2298475A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
ES2597843T3 (es) 2005-11-24 2017-01-23 Dompé Farmaceutici S.P.A. Derivados de (R)-arilalquilamino y composiciones farmacéuticas que los contienen
EP3498269A1 (en) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

Also Published As

Publication number Publication date
US20240180888A1 (en) 2024-06-06
LT4308114T (lt) 2026-03-25
DK4308114T3 (da) 2026-03-23
FI4308114T3 (fi) 2026-03-25
BR112023018826A2 (pt) 2024-03-12
WO2022195017A1 (en) 2022-09-22
HRP20260351T1 (hr) 2026-04-24
EP4308114B1 (en) 2026-02-11
JP2024512472A (ja) 2024-03-19
EP4308114A1 (en) 2024-01-24
IL305727A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
KR101991326B1 (ko) 오피오이드 수용체 리간드와 그 용도 및 제조방법
MXPA03011448A (es) Derivados de n-arilfenilacetamida y composicion farmaceutica que los contienen.
CN1921847B (zh) 氨基醇化合物
JP6217866B2 (ja) Ｋｃｎｑ２〜５チャネル活性化剤
JP6918166B2 (ja) 疼痛治療におけるｃｙｐ２ｊ２アンタゴニスト
EP4059497A1 (en) C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP4308114B1 (en) C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
CN102325768B (zh) 治疗疼痛和其他疾病的化合物和方法
JP6197971B1 (ja) Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
RU2857199C2 (ru) Предотвращение и лечение реакций гиперчувствительности к таксанам
TWI594991B (zh) 第一型類升糖素肽調節子及其用途
CN117337176A (zh) 用于治疗对紫杉烷类的超敏反应的c5ar1抑制剂
JP2005511639A (ja) 虚血性疾患の治療用ドパミン再取り込み阻害活性を有するトロパン誘導体
KR20190034609A (ko) 환상 아민 유도체의 결정 및 그 의약 용도
EP3215146B1 (en) Blt2 agonists for the treatment of pain
KR20130094811A (ko) 류코트리엔 관련 병증 치료용 페닐알킬 ｎ-히드록시우레아
EP4686469A1 (en) Cxcl8 inhibitors for use in the treatment of diabetes-associated comorbidities
Hao Discovery of Subtype Selective Agonists of the Group II Metabotropic Glutamate Receptors
HK40114112A (zh) 色胺前药
HK40091294B (zh) 色胺前药
HK40091294A (zh) 色胺前药
CN115397404A (zh) 用于治疗covid-19的cxcl8抑制剂
HK40114605A (zh) 色胺前药
HK40114252A (zh) 色胺前药
US20190135755A1 (en) Crystal polymorphism of kcnq2-5 channel activator

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260223

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260304

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260305